Covid-19 roundup: Pars­ing Bourla, a top an­a­lyst sees im­proved chances for Pfiz­er vac­cine; Fau­ci: No sur­prise that Trump was hit by Covid-19

3 years ago
Coronavirus

RBC's Bri­an Abra­hams holds a mock ad­comm on Bio­gen's iffy ad­u­canum­ab da­ta — and most of these ex­perts don't see a path to an ap­proval

3 years ago
R&D

Eu­ro­pean reg­u­la­tors spurn Agios' AML drug Tib­so­vo, un­con­vinced by the same thin PhI da­ta that won over the FDA

3 years ago
R&D
FDA+

Ameet Nath­wani re­bounds from Sanofi purge to helm Dew­point; Ali Mor­taza­vi named CEO at e-ther­a­peu­tics

3 years ago
Peer Review

The prospect of an Oc­to­ber OK large­ly closed, Pfiz­er's Al­bert Bourla promis­es not to sub­mit for EUA un­til No­vem­ber

3 years ago
People
Pharma

Gilead feels the heat as close al­ly Gala­pa­gos re­ports a big set­back on one of their top ex­per­i­men­tal drugs

3 years ago
R&D

Eli Lil­ly bags an ear­ly-stage biotech for the neu­ro team — pay­ing $135M cash and of­fer­ing $1B-plus in mile­stones

3 years ago
Deals

No­var­tis vet Dan­ny Bar-Zo­har leaps back in­to R&D, tak­ing over the de­vel­op­ment team at Mer­ck KGaA as Lu­ciano Ros­set­ti steps out

3 years ago
People

The Sanofi/Trans­late team hits the green light on an ear­ly-stage study for their mR­NA Covid-19 vac­cine af­ter see­ing it work in an­i­mals

3 years ago
R&D
Coronavirus

Astel­las wa­gers $425M-plus to buy a shot at hatch­ing a 'neur­al dust' break­through in bio­elec­tron­ics

3 years ago
Deals

Pa­tient death in piv­otal gene ther­a­py tri­al rat­tles Sarep­ta part­ner al­ready fac­ing clin­i­cal hold

3 years ago
R&D
Cell/Gene Tx

Ver­tex shares take a hit as liv­er tox forces the re­search team to scrap a PhII drug for AAT pa­tients. Will we see new deals now?

3 years ago
R&D

Vaxart was served a grand ju­ry sub­poe­na in Ju­ly over its con­tro­ver­sial role in OWS-fund­ed pre­clin­i­cal study

3 years ago
Pharma
FDA+

Covid-19 roundup: Mod­er­na starts lin­ing up po­ten­tial EU ap­proval for vac­cine; Hahn re­ject­ed White House push to re­brand EUA — Politi­co

3 years ago
Coronavirus

Canaan rais­es an­oth­er $800M as it launch­es its next fund with an em­pha­sis on biotech

3 years ago
Financing

Eli Lil­ly takes a one-two punch as Covid-19 an­ti­body com­bo study is halt­ed and man­u­fac­tur­ing ops fail in­spec­tion

3 years ago
Outsourcing
Coronavirus

A ma­jor new in­vestor just ar­rived at the biotech par­ty, as Evotec nets $295M from Mubadala and No­vo

3 years ago
Financing
Deals

Gos­samer shares take an­oth­er beat­ing as its lead drug fails 2 key clin­i­cal stud­ies, high­light­ing harsh re­views for DP2

3 years ago
R&D

Covid-19 roundup: Vaxart dos­es first pa­tient in new clin­i­cal vac­cine study; NI­AID launch­es study to find po­ten­tial ther­a­pies in re­pur­posed drugs

3 years ago
Coronavirus

An­oth­er safe­ty in­ci­dent trig­gers a halt to a piv­otal Covid-19 vac­cine study as J&J slams on the brakes

3 years ago
Coronavirus

Voy­ager shares take a hit as FDA slaps a hold on the IND for Hunt­ing­ton's gene ther­a­py — their #2 play in the pipeline

3 years ago
Cell/Gene Tx
FDA+

Sa­mi An­war raked in mil­lions of dol­lars gath­er­ing drug tri­al da­ta at his sites. But it was all a lie — and now he's been sen­tenced to 28 years

3 years ago
People
Pharma

Alk­er­mes like­ly head­ed for ap­proval af­ter ad­comm waves through schiz­o­phre­nia and bipo­lar pro­gram

3 years ago
FDA+

Covid-19 roundup: Pfiz­er strikes vac­cine deal with New Zealand, as CEO Al­bert Bourla de­fends de­vel­op­ment rush to crit­ics

3 years ago
Coronavirus
First page Previous page 153154155156157158159 Next page Last page